Dexcom Inc - DXCM STOCK NEWS

DexCom (DXCM) reported its Q4 and fiscal year 2024 results, with Q4 revenue growing 8% year-over-year to $1.114 billion. U.S. revenue increased 4% while international revenue grew 17%. Full-year revenue reached $4.033 billion, up 11% from 2023.

Q4 GAAP operating income was $188.9 million (17.0% of revenue), showing a 400 basis points decrease compared to Q4 2023. Net income was $151.7 million, or $0.38 per diluted share. The company maintained a strong cash position of $2.58 billion.

Strategic highlights include the FDA submission of Dexcom G7 15-day CGM system, secured reimbursement for Dexcom ONE+ in France, and a partnership with ŌURA. For 2025, Dexcom projects revenue of $4.60 billion (14% growth) with a Non-GAAP Operating Margin of approximately 21%.

DexCom (NASDAQ:DXCM) has announced its plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to review the performance.

Investors can access the conference call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using the confirmation ID '9430114'. A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.

DexCom (DXCM) has announced preliminary Q4 2024 results with total revenue of at least $1.113 billion, up 8% year-over-year. U.S. revenue reached approximately $803 million (4% growth), while international revenue hit $310 million (17% growth).

Full-year 2024 preliminary revenue totaled $4.032 billion, representing an 11% increase from 2023. The company updated its 2024 guidance, projecting non-GAAP gross profit margin of 62% and operating margin of 19%. Q4 gross margin was negatively impacted by inventory damage during transit and production yield issues.

Looking ahead to 2025, DexCom expects revenue of $4.60 billion, targeting 14% growth. The company forecasts 2025 non-GAAP gross profit margin of 64-65% and operating margin of 21%. Growth drivers include increased CGM access, Stelo rollout, and international expansion.

DexCom (NASDAQ:DXCM) has announced its upcoming participation at the 43rd Annual J.P. Morgan Healthcare Conference. The company's management will deliver a corporate update presentation on January 13, 2025, at 12:00 PM EST.

The presentation will be accessible through a live webcast, with links available on the Dexcom Investor Relations website at investors.dexcom.com. For those unable to attend live, the presentation will be archived on the website for future viewing.

Dexcom (NASDAQ:DXCM) has launched the first-ever Generative AI platform in glucose biosensing technology. The platform, built on Google Cloud's Vertex AI and Gemini models, will analyze individual health data patterns to reveal connections between lifestyle choices and glucose levels. Stelo, Dexcom's FDA-cleared over-the-counter glucose biosensor, is the first product to implement this GenAI technology through enhanced Weekly Insights, providing users with personalized recommendations on diet, exercise, and sleep.

The company plans to introduce additional GenAI-powered features throughout the next year to help users better understand their health information and make informed lifestyle decisions. This innovation reinforces Dexcom's position as a leader in glucose biosensing technology.

The Alberta Government now covers the Dexcom G7 Continuous Glucose Monitoring (CGM) System for eligible residents with type 1 or type 2 diabetes. Dexcom G7 has been added to the Alberta Drug Benefit List, expanding eligibility to include adults aged 18 and older. Residents under 18 must require ongoing insulin or insulin pump therapy, while those 18 and older must use an insulin pump, basal and bolus insulin, or premixed insulin. Dexcom G7 is designed to simplify diabetes management and lower A1C levels. The system offers features like quick sensor warm-up, predictive Urgent Low Soon alerts, and compatibility with various digital health apps. This move aligns Alberta with other Canadian regions, enhancing access to CGM technology. For more information, visit Dexcom's website.

Dexcom (NASDAQ:DXCM) and ŌURA have announced a strategic partnership to integrate Dexcom's glucose biosensor data with ŌURA's health metrics. The partnership includes a $75 million strategic investment from Dexcom in ŌURA's Series D funding, valuing ŌURA at over $5 billion. The companies will enable two-way data flow between their products and launch co-marketing efforts.

The first app integration is expected in the first half of 2025. ŌURA reported selling 2.5 million rings and expects to double annual sales to approximately $500 million in 2024. The partnership aims to provide users with comprehensive metabolic health management by combining glucose data with sleep, stress, heart health, and activity metrics.

Dexcom launches a global campaign for World Diabetes Day, revealing that nearly 70% of people with diabetes struggled to start their health journey post-diagnosis, and almost half felt in pursuing their passions. The company's survey across multiple countries shows 85% of respondents believe small steps in diabetes management lead to significant wellbeing improvements, while 84% of tech users affirm that CGM technology helps achieve their dreams. Dexcom is partnering with brand advocates and celebrities to encourage diabetics to share their aspirations on social media, offering a $500 giveaway in the U.S. to help winners start their journey.

DexCom (DXCM) reported Q3 2024 financial results with revenue growing 2% year-over-year to $994.2 million. U.S. revenue declined 2% while international revenue grew 12%. GAAP operating income was $152.0 million (15.3% of revenue), showing a 580 basis points decrease compared to Q3 2023. The company launched Stelo, the first over-the-counter glucose biosensor in the U.S. for adults with prediabetes and type 2 diabetes not on insulin therapy. DexCom reiterated its 2024 guidance with expected revenue of $4.00-4.05 billion and announced the retirement of Chief Commercial Officer Teri Lawver at year-end.